Econium is the trade name, generically known as Ebovitae for Injection, for the treatment of HIV-1 infected patients. Ebovitae for Injection is a long-acting HIV-1 fusion inhibitor, the world’s first long-acting HIV-1 fusion inhibitor, suitable for use in combination with other antiretroviral drugs for the treatment of HIV-1-infected patients with HIV-1 replication despite treatment with a variety of other antiretroviral drugs, and the drug has the unique advantages of low dosage frequency, a high barrier to resistance, and a high safety profile. Adverse effects include diarrhea, rash, headache, and gastroenteritis. It is usually contraindicated in patients who are allergic to this drug. After dissolution, the drug should be a clear and transparent solution, and should not be used if there is turbidity, precipitation, or foreign matter. The dissolved and prepared solution of this drug should be injected in a single drop, and should not be used in divided doses. Patients who want to use Ebovitae for Injection for treatment are advised to consult a professional doctor and use the drug for standardized treatment as prescribed by the doctor.